Opioid use disorder (OUD) refers to problematic patterns of opioid use that causes significant impairment or distress. Opioid addiction is treated through the use of medications such as methadone, buprenorphine or naltrexone in combination with counseling and behavioral therapies. The global opioid use disorder treatment market is gaining traction due to growing awareness regarding opioid abuse and associated health risks.

The global opioid use disorder (OUD) treatment market is estimated to be valued at US$ 3728.51 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
Availability of Novel Therapies
The market is expected to witness robust growth owing to the availability of novel drug therapies and management approaches to treat OUD. Several pharmaceutical companies are actively involved in developing newer formulations and drug delivery systems for OUD treatment. For instance, Indivior launched Perseris, the first once-monthly subcutaneous buprenorphine injection to treat moderate-to-severe OUD. Similarly, in 2021, the FDA approved Camurus' weekly and monthly subcutaneous buprenorphine formulations for the treatment of OUD. These novel subcutaneous and implant-based treatments offer increased medication adherence and convenience compared to oral therapies. Their availability is expected to boost market growth during the forecast period.

Porter's Analysis

Threat of new entrants: The threat of new entrants is moderate as the market is well established with high R&D and marketing costs required to enter.

Bargaining power of buyers: The bargaining power of buyers is moderate as there are many treatment options available and buyers can choose substitutes like non-opioid pain management therapies if needed.

Bargaining power of suppliers: The bargaining power of suppliers is high as they supply active ingredients required for opioid use disorder treatment drugs which require specialized manufacturing facilities.

Threat of new substitutes: The threat of new substitutes is high as new non-opioid treatment drugs and therapies are being researched which can overcome addiction.

Competitive rivalry: The competitive rivalry is high among existing players to gain market share by developing new advanced treatment drugs and solutions.

SWOT Analysis

Strengths: Wide treatment options available, growing awareness and support programs.

Weaknesses: Social stigma, high relapse rates, risk of overdose.

Opportunities: Potential for digital therapeutics, focus on preventive care.

Threats: New non-opioid substitutes, economic slowdowns reducing healthcare spends.

Key Takeaways

The global Opioid Use Disorder Market Growth is expected to witness high growth at a CAGR of 8.0% during the forecast period of 2024 to 2031.

Regional analysis - North America dominates the market currently due to the opioid crisis in the US. The Asia Pacific region is expected to grow fastest due to improving access to healthcare and growing alcohol and drug abuse.

Key players - Mundipharma, Orexo, Titan, Indivior, Alkermes, Molten Health, Hikma Pharmaceuticals, Avitus Group are some of the key players operating in the opioid use disorder market.

For more insights, read- https://www.pressreleasebulletin.com/opioid-use-disorder-market-trends-size-and-share-analysis/

For more details on the report,   Read- https://whotimes.com/change-harmony-exploring-the-dynamic-world-of-ion-exchange-membranes-for-applications/